Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CLTP001A12101
Novartis Pharmaceuticals
Healthy volunteers
1 trial -
COJR520A12101
Novartis Pharmaceuticals
Chronic Kidney Disease
1 trial -
CPDR001X2X01B
Novartis Pharmaceuticals
Different types of advanced cancer
1 trial -
CPIT565B12101
Novartis Pharmaceuticals
Systemic Lupus Erythematosus
1 trial -
CPIT565C12101
Novartis Pharmaceuticals
Rheumatoid Arthritis
1 trial -
CTNO155X2101
Novartis Pharmaceuticals
Advanced solid tumors
1 trial -
CVAY736J12101
Novartis Pharmaceuticals
Relapsed/refractory Non Hodgkin Lymphoma
1 trial -
INC280 single agent
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
Imatinib/Acetaminophen
Novartis Pharmaceuticals
Chronic Myeloid Leukemia (CML)
1 trial -
Indacaterol (QAB149)
Novartis Pharmaceuticals
Healthy
1 trial -
JSB462
Novartis Pharmaceuticals
Metastatic Prostate Cancer (mCRPC)
1 trial -
KFA115
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
1 trial -
LDK378
Novartis Pharmaceuticals
Anaplastic Lymphoma Kinase (ALK)
1 trial -
LDT600 (Telbivudine)
Novartis Pharmaceuticals
Chronic Hepatitis B
1 trial -
LEE011
Novartis Pharmaceuticals
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1 trial -
LGH447
Novartis Pharmaceuticals
Relapsed and Refractory Multiple Myeloma
1 trial -
LGH447
Novartis Pharmaceuticals
AML and High Risk MDS
1 trial -
MBG453
Novartis Pharmaceuticals
Myelodysplastic Syndromes
1 trial -
NIO752B12201
Novartis Pharmaceuticals
Alzheimer’s Disease
1 trial -
PDR001
Novartis Pharmaceuticals
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
1 trial -
PDR001
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
1 trial -
Phase I study of MGY825 in patients with lung cancer
Novartis Pharmaceuticals
Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients
1 trial -
QEQ278
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
1 trial -
Study of PIT565 in relapsed and/or refractory B-cell malignancies
Novartis Pharmaceuticals
Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.